Data: 2022 02 2F
Date: 2022.02.25
Your Name: Ziyun Li
Manuscript Title: The efficacy and safety of Wulingsan modified formulas for chronic heart failure patients: a meta analysis
Manuscript number (if known):
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	√None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
ŭ	testimony		
	testimony		
7	Company for attackling	o/ Name	
7	Support for attending meetings and/or travel	√None	
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data	√ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√ None	
10	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		
Dia	and accommended the above o	auflist of interest in the	following how
PIE	ase summarize the above c	onlict of interest in the	e lollowing box:
	There is no conflict of interest t	o declare.	
Ple	ase place an "X" next to the	e following statement to	o indicate your agreement:

Date: 2022.02.25
Your Name: Lang Ren
Manuscript Title: The efficacy and safety of Wulingsan modified formulas for chronic heart failure patients: a meta- analysis
Manuscript number (if known):
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	√None	
		Time forms much	26 mantha
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past√None	36 Months
3	Royalties or licenses	VNone	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_√None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	VNone	
8	Patents planned, issued or	√ None	
0	pending	\None	
	Poa0		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role		
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
	•		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	√ None	
13	financial interests	vNone	
	ase summarize the above c		llowing box:
Ple	ase place an "X" next to the	e tollowing statement to in	idicate your agreement:

Date: <u>Apr. 19th, 2022</u>			
Your Name: Renjun Gu			
Manuscript Title: The efficacy and safety of wulingsan modified formulas for chronic heart failure patients: a			
systematic review and meta-analysis			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	_ XNone	

5	Payment or honoraria for	_ XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	_ XNone	
7	Support for attending meetings and/or travel	_ XNone	
	-		
8	Patents planned, issued or	_ XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or	_ XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	_ XNone	
	group, paid or unpaid		
11	Stock or stock options	_ XNone	
12	Receipt of equipment,	_ XNone	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-	_ XNone	
	financial interests	_	

Please summarize the above conflict of interest in the following box:

None	

Please place an "X" next to the following statement to indicate your agreement:

Date: 2022.02.25 Your Name: Conghui Zhou Manuscript Title: The efficacy and safety of Wulingsan modified formulas for chronic heart failure patients: a meta analysis
Manuscript number (if known):
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).	,	
3	Royalties or licenses	√None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	_√ None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
	testimony	_	
7	Command for additional to a	A Name	
7	Support for attending meetings and/or travel	√None	
8	Patents planned, issued or	√ None	
	pending		
	penang		
0	Dauticia etica e a Data	A North	
9	Participation on a Data		
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√ None	
13	financial interests	None	
	illialicial lifterests		
Ple	ase summarize the above o	onflict of interest in the	following box:
	There is no conflict of interest to declare.		
Ple	ase place an "X" next to the	e following statement to	indicate your agreement:

Date: 2022.02.25	
Your Name: Xu Tong	
Manuscript Title: The efficacy and analysis	safety of Wulingsan modified formulas for chronic heart failure patients: a meta-
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_√None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	√None	
8	Patents planned, issued or	√ None	
0	pending	VNOTIE	
	Po0		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
	•		
12	Receipt of equipment,	√None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	√ None	
13	financial interests		
	ase summarize the above c		llowing box:
plم	ase place an "X" next to the	e following statement to in	idicate vour agreement:

Date: 2022.02.25 Your Name: Jingqing Hu Manuscript Title: The efficacy and safety of Wulingsan modified formulas for chronic heart failure patients: a meta-			
analysis			
Manuscript number (if known):			
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment			
to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a			

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations,	√None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
	,		
7	Support for attending	√ None	
,	meetings and/or travel		
	meetings and/or traver		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data	√ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√ None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√ None	
	Stock of Stock options		
12	Receipt of equipment,	√ None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√ None	
13	financial interests	\None	
	illianciai iliterests		
Ple	ase summarize the above c	onflict of interest in the	e following box:
	There is no conflict of interest to declare.		
L			
Ple	ase place an "X" next to the	e following statement t	o indicate your agreement: